title: Characteristics of adrenaline-driven receptor-mediated signals in human microvessel-derived endothelial cells.
abstract: Adrenaline (0.001-1,000 muM) strongly stimulated adenosine-3',5'cyclic monophosphate (cAMP) generation in cultured human microvascular-derived endothelial cells (HMEC-1). Isoprenaline mimicked the action of adrenaline, whereas noradrenaline appeared to be decisively less potent. Experiments carried out with an array of compounds acting selectively on different types/subtypes of adrenergic receptors revealed that the adrenaline cAMP effect in HMEC-1 cells did not possess either an alpha(1) or alpha(2) component. However, the effect may have been mediated through a receptor that did not fit beta(1)-, beta(2)-, or beta(3)-receptor classification. Supporting this assertion, various double and triple beta-subtype selective drug combinations maximally inhibited the adrenaline effect by 50-60%, whereas the non-selective antagonist propranolol totally prevented the hormone-evoked cAMP effect. Based on results utilizing the phosphodiesterase (PDE)-isoform nonselective inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the PDE-4-selective inhibitor rolipram, the adrenaline-driven cAMP signal appeared to be regulated by PDE-4. In addition, the present study demonstrated that phenylephrine, a presumed selective alpha(1)-adrenoceptor agonist, was capable of stimulating cAMP generation in HMEC-1 cells in a prazosin-insensitive and propranolol-sensitive manner. This result indicated that in at least this cell model system, phenylephrine may act nonspecifically. Microvessel-derived endothelial cells such as HMEC-1 exhibit functional differences when compared with macrovessel-derived endothelial cells (e.g. HUVEC sensitivity to adrenaline). Accordingly, these cell cultures represent a useful model system to study the biological effects of endogenous catecholamines, including adrenaline, as well as potential therapeutics targeting adrenergic receptors.
authors.affiliation: Departament of Pharmacology, Chair of Pharmacology and Clinical Pharmacology, Medical University of Łódź, Zeligowskiego 7/9, PL 90-752 Łódź, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Wiktorowska-Owczarek
authors.forename: Magdalena
authors.initials: M
authors.lastname: Namiecińska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Berezińska
authors.forename: Jerzy Z
authors.initials: JZ
authors.lastname: Nowak
mesh_terms: D002478:Cells, Cultured; D000242:Cyclic AMP / Q000096:biosynthesis*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000502:physiology; D042783:Endothelial Cells / Q000378:metabolism*; D004837:Epinephrine / Q000494:pharmacology*; D006801:Humans; D055806:Microvessels / Q000166:cytology*; D011433:Propranolol / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D015398:Signal Transduction
chemical_list: D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011433:Propranolol; D000242:Cyclic AMP; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004837:Epinephrine